// App-Quantinova.ai

2414 : ADAR1-dependent RNA editing is a mechanism of therapeutic resistance in human plasma cell malignancies

Researchers

Presenter

  • Elisa Lazzari

Principal Investigators

  • Leslie A. Crews

  • Christina Wu

  • Heather Leu

  • Shawn Ali

  • Raffaella Chiaramonte

  • Mark Minden

  • Caitlin Costello

  • Catriona H.M. Jamieson

Medical Centers

  • Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center at University of California, San Diego, San Diego, CA

  • Department of Health Sciences, Univeristy of Milan, Milan, Italy

  • Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, ON, Canada

  • Department of Medicine, Moores Cancer Center at University of California, San Diego, San Diego, CA.

Locations

  • United States

  • Canada

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Primary plasma cell leukemia

  • Multiple Myeloma

  • Solid malignancies

Biomarkers

  • Adenosine deaminase RNA specific

Drug/Treatment

  • Adenosine

  • Adenosine Intravenous

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved